Skip to main content
JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal.
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.
Therapy-induced malignant neoplasms in Nf1 mutant mice.
JAKing up hematopoietic proliferation.
Focus on myeloproliferative diseases and myelodysplastic syndromes.
The sum is greater than the FGFR1 partner.
Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells.
Acute leukemia: a pediatric perspective.